证券代码：688029 证券简称：南微医学 公告编号：2024-062 南微医学科技股份有限公司 关于 2025 年度日常关联交易额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：是 2024 年 12 月 23 日，南微医学科技股份有限公司（以下简称"公司"）第 四届董事会审计委员会以及第四届董事会 2024 年第一次独立董事专门会议分别 审议通过了《关于 2025 年度日常关联交易额度预计的议案》并同意提交公司董 事会审议。 公司于 2024 年 12 月 24 日召开第四届董事会第六次会议、第四届监事会第 五次会议，审议通过了《关于 2025 年度日常关联交易额度预计的议案》，本次 日常关联交易预计金额合计为 13,444.77 万元人民币，为向关联人采购商品、采 购劳务的关联交易，出席会议的公司董事、监事一致同意该议案。 本次日常关联交易额度预计事项尚需提交股东大会审议。 （二）本次日常关联交易预计金额和类别 单位：万元 日常关联交易对公司的影响：本次关联交易 ...

扫码添加梧桐小师弟 免费领取电子资料 Hello, 这是上交所发布的并购资 料集，保存压缩包到电脑解压即可 a 上交所: 并购一本通 +典型案...30例）.zip 16.02MB 《上市公司并购重组典型案例汇编(30例)》 《并购重组规则、政策与案例一本通 上交所《上市公司并购重组典型案例汇编(30 ... PDF 01.青岛海尔多次产业并购实现跨越式发展 02.产业整合：沃尔德差异化对价购买鑫金泉 昊华科技实施同一控制下产业整合案例 04.持续注入优质资产:长江电力收购水电资产 DF 05.普源精电:提前锁定+分步实施 06.南微医学收购CME: 拓宽海外渠道,加速... 07.大股东注资型产业整合：中直股份收购直升 ... 08.中文传媒：发行股份及支付现金购买资产 PDF 09.跨界并购:安孚科技收购南孚电池 10.小额快速:长岭液压收购江阴尚驰 11.士兰微收购亏损子公司少数股权 12.定向可转债: 思瑞浦收购创芯微 13.定向可转债:华电国际购买少数股权 14.境外收购：闻泰科技收购安世半导体 15.洛阳铝业：多次重大资产购买 17.首旅酒店收购如家酒店集团,打造全国领先 ... 16.长电科技要 ...

证券代码：688029 证券简称：南微医学 公告编号：2024-061 南微医学科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/16，由公司董事长隆晓辉先生提议 | | | --- | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 6 个月 | | | 预计回购金额 | 2,000 万元 | 万元~4,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 187,338 | 股 | | 累计已回购股数占总股本比例 | 0.10% | | | 累计已回购金额 | | 11,086,557.13 元 | | 实际回购价格区间 | 55.85 元/股 | 元/股~62.74 | 一、 回购股份的基本情况 2024 年 7 月 15 日，公司召开第三届董 ...

扫码添加梧桐小师弟 免费领取电子资料 Hello, 这是上交所发布的并购资 料集，保存压缩包到电脑解压即可 a 上交所: 并购一本通 +典型案...30例）.zip 16.02MB 《上市公司并购重组典型案例汇编(30例)》 《并购重组规则、政策与案例一本通 上交所《上市公司并购重组典型案例汇编(30 ... PDF 01.青岛海尔多次产业并购实现跨越式发展 02.产业整合：沃尔德差异化对价购买鑫金泉 昊华科技实施同一控制下产业整合案例 04.持续注入优质资产:长江电力收购水电资产 DF 05.普源精电:提前锁定+分步实施 06.南微医学收购CME: 拓宽海外渠道,加速... 07.大股东注资型产业整合：中直股份收购直升 ... 08.中文传媒：发行股份及支付现金购买资产 PDF 09.跨界并购:安孚科技收购南孚电池 10.小额快速:长岭液压收购江阴尚驰 11.士兰微收购亏损子公司少数股权 12.定向可转债: 思瑞浦收购创芯微 13.定向可转债:华电国际购买少数股权 14.境外收购：闻泰科技收购安世半导体 15.洛阳铝业：多次重大资产购买 17.首旅酒店收购如家酒店集团,打造全国领先 ... 16.长电科技要 ...

证券代码：688029 证券简称：南微医学 公告编号：2024-060 南微医学科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 投资者可于 2024 年 11 月 22 日(星期五)至 11 月 28 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或将有关问题通过电子 邮件的形式发送至公司投资者关系邮箱 nwyx@micro-tech.com.cn。公司将在 说明会上对投资者普遍关注的问题进行回答。 南微医学科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日在 上海证券交易所网站（www.sse.com.cn）披露《2024 年第三季度报告》。为便于 广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司 计划于 2024 年 11 月 29 日举行 2024 年第三季度业绩说明会，就投资者关心的问 题 ...

Investment Rating - The report maintains an "Overweight" rating for the company [2] Core Views - The company's products for early screening of digestive tract tumors are expected to benefit from increasing penetration and popularity of endoscopic diagnosis and treatment in China [5] - Channel expansion to grassroots levels is expected to raise the industry's growth ceiling [5] - New product lines, including visualization products, are expected to contribute to future performance growth [5] - Overseas revenue is expected to continue growing as the company improves its international product pipeline and marketing reforms [5] Financial Analysis - In the first three quarters of 2024, the company achieved operating revenue of RMB 2.012 billion, a year-on-year increase of 15.30% [6] - Net profit attributable to the parent company was RMB 451 million, a year-on-year increase of 16.70% [6] - In Q3 2024, operating revenue was RMB 679 million, a year-on-year increase of 13.44% [6] - Net profit attributable to the parent company in Q3 2024 was RMB 141 million, a year-on-year increase of 15.06% [6] - Sales expenses in the first three quarters of 2024 were RMB 465 million, a year-on-year increase of 21.55%, with a sales expense ratio of 23.11%, an increase of 1.18 percentage points year-on-year [4] - Management expenses were RMB 249 million, a year-on-year increase of 10.10%, with a management expense ratio of 12.38%, a decrease of 0.59 percentage points year-on-year [4] - R&D expenses were RMB 112 million, a year-on-year increase of 8.74%, with an R&D expense ratio of 5.54%, a decrease of 0.34 percentage points year-on-year [4] Profit Forecast and Valuation - The company's EPS for 2024-2026 is forecasted to be RMB 3.11, RMB 3.80, and RMB 4.62, respectively [5] - The corresponding P/E ratios are 25.0x, 20.4x, and 16.8x based on the closing price on November 11, 2024 [5] - Operating revenue is expected to grow by 15.1%, 20.8%, and 20.9% in 2024-2026, respectively [3] - Net profit attributable to the parent company is expected to grow by 20.1%, 22.4%, and 21.5% in 2024-2026, respectively [3] - Gross margin is expected to be 66.6%, 66.7%, and 67.1% in 2024-2026, respectively [3] - ROE is expected to be 15.0%, 16.2%, and 17.2% in 2024-2026, respectively [3] Key Financial Indicators - Total assets in 2023 were RMB 4.566 billion, with net assets of RMB 3.731 billion [1] - Earnings per share (EPS) in 2023 was RMB 2.59 [3] - The company's P/E ratio in 2023 was 30.0x [3] - The company's net profit margin in 2023 was 20.2% [9] - The company's asset turnover ratio in 2023 was 58.2% [9]

Investment Rating - The report maintains a "Buy" rating for the company [1][3] Core Views - Q3 performance showed steady growth, with revenue reaching 6.79 billion yuan, a year-on-year increase of 13.44%, and net profit attributable to shareholders of 1.41 billion yuan, up 15.06% year-on-year [1] - Overseas markets performed strongly, with revenue from the Americas growing 19.2% year-on-year, and EMEA markets growing 36.5% year-on-year [1] - The company's gross margin improved to 67.06% in Q3, driven by cost reduction and efficiency improvements, as well as strong growth in tumor intervention products [1] - New products, such as visualization devices, are gaining traction in both domestic and international markets, with over 750 units sold domestically and 40 million yuan in sales in overseas markets [1] Financial Performance Summary - For 2024Q1-Q3, the company achieved revenue of 20.12 billion yuan, a year-on-year increase of 15.31%, and net profit attributable to shareholders of 4.51 billion yuan, up 16.70% year-on-year [1] - The company's revenue is expected to grow to 27.88 billion yuan in 2024, 33.81 billion yuan in 2025, and 41.39 billion yuan in 2026, with year-on-year growth rates of 15.6%, 21.3%, and 22.4%, respectively [1] - Net profit attributable to shareholders is projected to reach 5.85 billion yuan in 2024, 7.27 billion yuan in 2025, and 9.09 billion yuan in 2026, with growth rates of 20.4%, 24.2%, and 25.0%, respectively [1] Overseas Market Expansion - The company has been actively expanding its overseas sales channels, including acquiring mature channels in Europe and increasing investment in markets such as Japan and Australia [1] - The construction of a factory in Thailand is accelerating, which is expected to further boost overseas market sales [1] - In Q3, overseas revenue accounted for a significant portion of total revenue, with the Americas contributing 1.44 billion yuan, EMEA contributing 1.24 billion yuan, and Kangyou Medical contributing 730 million yuan [1] New Product Development - Visualization products have seen rapid adoption, with over 750 units sold domestically and 40 million yuan in sales in overseas markets [1] - New products, such as the pancreatic cyst product and the three-arm clip, are progressing well in terms of registration and market access, with the three-arm clip expected to be launched in Japan and approved in Europe by the end of the year [1] - The company's pipeline of new products, including the bile duct micro-instruments, is expected to drive long-term growth, with the bile duct micro-instruments anticipated to receive U.S. approval in Q1 2025 [1]

证券代码：688029 证券简称：南微医学 公告编号：2024-059 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南微医学科技股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，上市公司在实施回购期间，应当在每个月的前 3 个 交易日内披露截至上月末的回购进展情况。现将公司回购进展情况公告如下： 2024 年 10 月，公司未回购股份。截至 2024 年 10 月 31 日，公司已累计回购 股份 187,338 股，占公司总股本的比例为 0.10%，购买的最高价为 62.74 元/股、 最低价为 55.85 元/股，已支付的总金额为 11,086,557.13 元（不含印花税、交易 佣金等交易费用）。 上述回购股份符合法律法规的规定及公司回购股份方案。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据 ...

Investment Rating - Maintains an "Overweight" rating with a target price of RMB 92.25, up from the previous target of RMB 76.51 [4] Core Views - Domestic growth is under pressure due to centralized procurement, but dealer inventory has normalized, indicating potential for future growth [2][3] - Overseas markets continue to grow rapidly, with strong performance in Asia-Pacific, Americas, and EMEA regions [3] - New products are receiving positive feedback, supporting the company's growth trajectory [2][3] Financial Performance - Q3 2024 revenue reached RMB 679 million, a 13.44% YoY increase, with net profit attributable to shareholders at RMB 141 million, up 15.06% YoY [3] - Domestic revenue in Q3 2024 was RMB 323 million, a 2% YoY decline, while overseas revenue grew 27% YoY to RMB 350 million [3] - Gross margin improved to 67.06%, up 2.44 percentage points YoY, driven by automation and cost optimization [3] Market and Product Development - The company has expanded its presence in the US, covering over 500 hospitals and 1,000 outpatient surgery centers, with a current market share of around 5% [3] - In Europe, the company is strengthening its direct sales channels and has signed a merger agreement with CME, which has a comprehensive sales network across Europe [3] - Visualized products are performing well, with over 750 hospital installations in the first three quarters of 2024, compared to nearly 500 in 2023 [3] Financial Forecasts - EPS forecasts for 2024-2026 have been revised to RMB 3.07, RMB 3.69, and RMB 4.36, down from previous estimates of RMB 3.21, RMB 3.92, and RMB 4.77 [3] - Revenue is expected to grow to RMB 2.755 billion in 2024, RMB 3.221 billion in 2025, and RMB 3.732 billion in 2026 [10] - Net profit attributable to shareholders is projected to reach RMB 577 million in 2024, RMB 694 million in 2025, and RMB 820 million in 2026 [10] Valuation and Market Data - The company's market capitalization is RMB 13.6 billion, with a current stock price of RMB 72.40 [5] - The stock has a 52-week price range of RMB 56.60 to RMB 98.82 [5] - The company's P/E ratio is expected to decrease from 23.57 in 2024 to 16.59 in 2026 [10]

Financial Performance - In Q3 2024, the company achieved a revenue of 679 million CNY, a 13.4% increase from 598 million CNY in the same period last year [2] - The gross profit margin for Q3 2024 was approximately 67.1%, up by 2.3 percentage points year-on-year [2] - Net profit for Q3 2024 reached 141 million CNY, a 15.1% increase from 122 million CNY in the previous year [2] - For the first three quarters of 2024, total revenue was 2.012 billion CNY, a 15.3% increase from 1.745 billion CNY in the same period last year [2] Market Performance - Revenue from the Asia-Pacific market was about 338 million CNY, showing slight growth, while domestic revenue slightly declined due to centralized procurement impacts [2] - The Americas market generated 144 million CNY, with a year-on-year growth of 19.2%, and the U.S. local business grew by 33% [2] - The EMEA market revenue was 124 million CNY, reflecting a 36.5% increase [2] Research and Development - R&D expenses for Q3 2024 were approximately 42 million CNY, a 23.8% increase year-on-year, accounting for about 6.2% of sales revenue [2] - The company is focusing on high-potential core projects, including innovative products in the pipeline [5] Strategic Responses - The company is adapting to challenges from domestic centralized procurement by reducing inventory and adjusting product structures [3] - Plans to enhance overseas market presence include increasing investment in Europe, Japan, and Australia, alongside channel acquisitions [5] - The company aims to maintain a strong growth trajectory in international sales, expecting that by 2025, international sales will surpass domestic sales [5] Future Outlook - The company is optimistic about the domestic market, anticipating significant growth potential compared to developed countries [5] - Continuous innovation and product launches are planned to counteract price declines and stabilize market performance [5] - The company is committed to improving patient outcomes and achieving high-quality development through collaboration with global healthcare professionals [5]